StockUS listing USEVAXNASDAQHealthcareEarnings Deterioration

Evaxion Biotech AS(EVAX) Stock Analysis | Healthcare

USD --+0.00%
Reward44Moderate
Risk35Moderate
75%Data
Thin -116% profit margin · Revenue down 100% YoY
USD —+0.00 (+0.00%) Previous close · NASDAQ
Market cap 20.75M
Reward Ratingⓘ44 Moderate reward assessment · 75% data coverage
Bottom 25% of stocksView factors
Risk Ratingⓘ35 Moderate risk assessment
Risk factors availableUnlock details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on EVAX to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Evaxion Biotech AS?

Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines.

AI Brief Pro

The brief on Evaxion Biotech AS

The story behind the price, the case for and against, and what could go wrong. Open a part to read it.

What is Evaxion Biotech AS?

Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of advanced melanoma; EVX-03, DNA-based cancer vaccine for the treatment of solid tumors; and EVX-04, a therapeutic cancer vaccine candidate, which is in phase 1 trial for acute myeloid leukemia. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 20.75M.

Financial Highlights

Investment Breakdown

Growth
Revenue growth is subdued, limiting near-term earnings expansion.
Profitability
Thin or inconsistent margins weigh on earnings quality.
Risk
Below-average volatility supports a steadier risk profile.
Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (44)

Similar stocks to compare

A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.

Company Information
SectorHealthcare
IndustryBiotechnology
Beta0.563
Insider Activity
12M windowNo data
No insider activity data available for this ticker.